Patents Assigned to Sankyo Company Limited
  • Publication number: 20210009709
    Abstract: This application relates to a pharmaceutical composition for use in a method for treating and/or preventing a patient having ectopic ossification and/or brain tumor, wherein the patient has an active mutation in ALK2 protein which is responsible for ectopic ossification or brain tumor; an amino acid residue at position 330 of ALK2 is proline; and an active ingredient of this composition is an anti-ALK2 antibody or an antigen-binding fragment thereof comprising a property of binding to ALK2, a property of cross-linking ALK2, and a property of inhibiting BMP signal transduction.
    Type: Application
    Filed: March 4, 2019
    Publication date: January 14, 2021
    Applicants: SAITAMA MEDICAL UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Takenobu KATAGIRI, Sho TSUKAMOTO, Keigo KUMAGAI, Shinnosuke TSUJI
  • Publication number: 20210008069
    Abstract: The present invention aims to provide a pharmaceutical drug that contains a compound having an excellent therapeutic effect on inflammatory bowel disease. A therapeutic agent for inflammatory bowel disease, containing as an active ingredient a compound represented by formula (I), wherein R1 represents a hydroxy C1-C6 alkyl group, a C2-C7 alkanoyl group, a C2-C7 alkanoyl C1-C6 alkyl group, a (C1-C6 alkoxy) carbonyl group, a (C1-C6 alkoxy) carbonyl C1-C6 alkyl group, a carboxy group or a carboxy C1-C6 alkyl group, or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: February 18, 2019
    Publication date: January 14, 2021
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Yuki TOYOSHIMA
  • Patent number: 10881734
    Abstract: The present invention provides a pharmaceutical composition or a diagnostic composition targeting human fibroblast growth factor receptor 2 (hFGFR2).
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: January 5, 2021
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Chigusa Yoshimura, Reimi Kawaida, Kokichi Honda
  • Publication number: 20200407394
    Abstract: The present invention establishes a molecular therapy for glycogen storage disease type Ia. The present invention provides an oligonucleotide of 15-30 bases comprising a nucleotide sequence complementary to the cDNA of G6PC gene with c.648G>T mutation, wherein the oligonucleotide comprises a sequence complementary to a region comprising any site between the 82nd to the 92nd nucleotide from the 5? end of exon 5 of the G6PC gene with c.648G>T mutation, a pharmacologically acceptable salt or solvate thereof. Also provided is a pharmaceutical drug comprising the oligonucleotide, a pharmacologically acceptable salt or solvate thereof (e.g., therapeutic drug for glycogen storage disease type Ia).
    Type: Application
    Filed: March 5, 2019
    Publication date: December 31, 2020
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, KOBE GAKUIN EDUCATIONAL FOUNDATION
    Inventors: Makoto KOIZUMI, Yoshiyuki ONISHI, Takeshi MASUDA, Mitsuhiro IWAMOTO, Yukiko SEKIGUCHI, Kentaro ITO, Shinnosuke TSUJI, Masafumi MATSUO
  • Publication number: 20200390900
    Abstract: It is an object of the present invention to provide an antibody binding to CDH6 and having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like. The present invention provides an anti-CDH6 antibody having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.
    Type: Application
    Filed: September 2, 2020
    Publication date: December 17, 2020
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Atsuko SAITO, Tsuyoshi HIRATA, JP NAKAMURA
  • Publication number: 20200392496
    Abstract: Provided is a short-chain guide RNA that is able to induce site-specific editing even when only a small number of nucleotides is attached to the target recognition site. The guide RNA includes a first oligonucleotide that identifies the target RNA, and a second oligonucleotide that links to the 3? end of the first oligonucleotide. The first oligonucleotide contains: a target-corresponding nucleotide residue that corresponds to an adenosine residue in the target RNA; an oligonucleotide of 15 to 30 residues that links to the 5? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA; and an oligonucleotide of 3 or 4 residues that links to the 3? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA. The second oligonucleotide contains 2 to 24 nucleotide residues, and induces site-specific editing of the target RNA.
    Type: Application
    Filed: December 5, 2018
    Publication date: December 17, 2020
    Applicants: FUKUOKA UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Masatora FUKUDA
  • Publication number: 20200384121
    Abstract: A method for producing a compound represented by formula (C) wherein R1 represents an amino group protected with a protecting group, the method comprising a step of subjecting a compound represented by formula (B) wherein R1 represents the same meaning as above, to intramolecular cyclization to convert the compound into the compound represented by formula (C).
    Type: Application
    Filed: August 30, 2018
    Publication date: December 10, 2020
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoshio NISHI, Kohei SAKANISHI, Shigeru NOGUCHI, Tadahiro TAKEDA
  • Publication number: 20200385486
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.
    Type: Application
    Filed: August 19, 2020
    Publication date: December 10, 2020
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroyuki NAITO, Yusuke OGITANI, Takeshi MASUDA, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Koji MORITA, Hideki MIYAZAKI, Yuji KASUYA, Ichiro HAYAKAWA, Yuki ABE
  • Publication number: 20200385422
    Abstract: Crystals of the compound represented by formula (1), a method for the production thereof, and a method for producing an antibody-drug conjugate using the crystals.
    Type: Application
    Filed: August 30, 2018
    Publication date: December 10, 2020
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Tatsuya YAMAGUCHI, Takashi KOUKO, Shigeru NOGUCHI, Yohei YAMANE, Fumikatsu KONDO, Takahiro AOKI, Tadahiro TAKEDA, Kohei SAKANISHI, Hitoshi SATO, Tsuyoshi UEDA, Shinji MATUURA, Kei KURAHASHI, Yutaka KITAGAWA, Tatsuya NAKAMURA
  • Publication number: 20200377573
    Abstract: It is intended to provide a novel peptide. The present invention provides a peptide which comprises the amino acid sequence shown in SEQ ID NO: 30 and inhibits protease activity.
    Type: Application
    Filed: December 21, 2017
    Publication date: December 3, 2020
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Daisuke Nishimiya, Ryuji Hashimoto, Toshiyuki Sato, Takako Kimura, Atsushi Yamasaki, Tatsuya Inoue
  • Patent number: 10851092
    Abstract: The present invention relates to a compound having RET kinase inhibiting action or a pharmaceutically acceptable salt thereof, useful in the treatment of diseases such as cancer. In particular a compound represented by the following general formula (I) as defined herein: (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: December 1, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Hiroaki Inagaki, Yoshihiro Shibata, Hidenori Namiki, Hideaki Kageji, Kiyoshi Nakayama, Yasuyuki Kaneta
  • Patent number: 10851111
    Abstract: The present disclosure provides a method for efficiently producing and providing compounds having a spirooxindole skeleton, for example compounds having a spirooxindole skeleton and having antitumor activity that inhibit the interaction between Mdm2 protein and p53 protein, or intermediates thereof, using an asymmetric catalyst. Compounds having optically active tricyclic dispiroindole skeletons are obtained through catalytic asymmetric 1,3-dipolar cycloaddition reaction using ketimine as a reaction substrate and using a chiral ligand and a Lewis acid.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: December 1, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Motoshi Yamauchi, Keiji Nakayama
  • Patent number: 10851162
    Abstract: It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: December 1, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Tomoaki Komai, Takako Kimura, Daichi Baba, Yoshikuni Onodera, Kento Tanaka, Takashi Kagari, Anri Aki, Nobumi Nagaoka
  • Publication number: 20200362032
    Abstract: It is an object of the present invention to provide an antibody specifically binding to GPR20-positive tumor cells such as GIST, a pharmaceutical product comprising the antibody and having therapeutic effects on a tumor, a method for treating a tumor using the aforementioned pharmaceutical product, and the like. It is another object of the present invention to provide an anti-GPR20 antibody having internalization activity, an antibody-drug conjugate containing the antibody, and the like.
    Type: Application
    Filed: August 11, 2020
    Publication date: November 19, 2020
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kenji IIDA, Takehiro HIRAI, Tomoko TERAUCHI, Kensuke NAKAMURA
  • Publication number: 20200362033
    Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.
    Type: Application
    Filed: July 26, 2018
    Publication date: November 19, 2020
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Keisuke FUKUCHI, Kayoko NANAI, Masato AMANO, Kozo YONEDA, Yusuke TOTOKI, Shoji YAMAMOTO
  • Publication number: 20200352964
    Abstract: An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.
    Type: Application
    Filed: July 24, 2020
    Publication date: November 12, 2020
    Applicants: SANTEN PHARMACEUTICAL CO., LTD., DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoko ENDO, Kyohei TAKAHASHI, Shinya UMEZAKI
  • Publication number: 20200347030
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: A: e.g., Benzene, E: e.g., —CH2—, G: e.g., a 5-membered aromatic heterocyclic ring, X: e.g., cyclohexane, J: e.g., a 5-membered aromatic heterocyclic ring, Y: e.g., a phenyl group, R1, R2, R3: e.g., a halogen atom, R4: e.g., a C1-C6 alkyl group, R5: e.g., a hydrogen atom, R6a, R6b, R6c, R6d: e.g., a hydrogen atom, R7: e.g., a hydrogen atom, R8: e.g., a hydrogen atom, n1, n2, n3: e.g., 1.
    Type: Application
    Filed: September 13, 2018
    Publication date: November 5, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Toru Taniguchi, Osamu Iwamoto, Keiji Saito, Katsuyoshi Nakajima, Yasuyuki Ogawa, Nobuya Kurikawa, Seiko Nagata, Kaori Ito, Eriko Kioi
  • Patent number: 10822336
    Abstract: Provided are novel crystals of [2-(1-methyl-1H-pyrazol-4-yl)-6-(morpholin-4-yl)-9H-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanone and a pharmaceutically acceptable salt thereof having advantageous characteristics. [2-(1-Methyl-1H-pyrazol-4-yl)-6-(morpholin-4-yl)-9H-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanone and a pharmaceutically acceptable salt thereof provided by the present invention are excellent in stability and have satisfactory physical properties as a drug substance of a pharmaceutical product.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: November 3, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yasushi Ueda, Sagar Ramdas Amale, Manjunath Govind Bhovi
  • Publication number: 20200330415
    Abstract: An object of the present invention is to provide a medicine that can simply treat and/or prevent a retinal degenerative disease associated with photoreceptor degeneration, including retinitis pigmentosa. The solution is to provide an agent for treating and/or preventing a retinal degenerative disease associated with photoreceptor degeneration, containing a compound having a retinoic acid receptor agonistic activity (for example, tamibarotene, tamibarotene methyl ester, tamibarotene ethyl ester, tazarotene, tazarotenic acid, adapalene, palovarotene, retinol, isotretinoin, alitretinoin, etretinate, acitretin or bexarotene) or a salt thereof.
    Type: Application
    Filed: July 3, 2018
    Publication date: October 22, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Naoki Tsuji, Masumi Ueno
  • Patent number: 10808006
    Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: October 20, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki